Bullboard - Stock Discussion Forum Zosano Pharma Corporation ZSANQ

Healthcare Biotechnology

Zosano Pharma Corp is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Zosano Pharma Corp is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K... see more

Add To Watchlist

EXPM:ZSANQ - Post Discussion

Zosano Pharma Corporation > ZSAN LAUNCHES PHASE 2/3 STUDY FOR CLUSTER HEADACHE

View:

Post by Humanist on Oct 25, 2019 9:36am

ZSAN LAUNCHES PHASE 2/3 STUDY FOR CLUSTER HEADACHE

Zosano launches Phase 2/3 study of zolmitriptan for cluster headache
Oct. 24, 2019 10:33 AM ET|About: Zosano Pharma Corporation (ZSAN)|By: Douglas W. House, SA News Editor

Enrollment is underway in a 120-subject Phase 2/3 clinical trial evaluating Zosano Pharma's (ZSAN +3.5%) C213 (zolmitriptan) for the acute treatment of cluster headache.

C213 is a patch worn on the skin based on the company's ADAM technology, drug-coated titanium micro-projections that deliver the drug through the skin. It is the same approach used with migraine patch Qtrypta.

The co-primary endpoints are the proportion of patients achieving pain relief within 15 minutes and the proportion of patients achieving sustained pain relief (15 minutes to 60 minutes).
The estimated completion date is April 2021.